News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Esperion Therapeutics, Inc. Presents Full Results of Phase 2 Clinical Trial Showing Its Novel Oral Therapy ETC-1002 Lowered LDL-C By Up to 43 Pct in Hypercholesterolemic Patients With Type 2 Diabetes


5/3/2013 11:04:59 AM

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

LAKE BUENA VISTA, Fla.--(BUSINESS WIRE)--Please replace the release with the following corrected version due to multiple revisions. Esperion Therapeutics, Inc., a privately-held clinical-stage biopharmaceutical company focused on developing and commercializing first-in-class, oral low-density lipoprotein cholesterol (LDL-C) lowering therapies for the treatment of hypercholesterolemia and other cardiometabolic disorders, today announced full results of a Phase 2 clinical trial of ETC-1002 in patients with Type 2 diabetes and hypercholesterolemia. The trial met its primary endpoint, demonstrating that ETC-1002 lowered LDL-C by up to 43 percent and was associated with improvements in control of other cardiometabolic risk factors. In addition, ETC-1002 was well tolerated.

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES